Compare PTGX & ERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTGX | ERO |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 3.2B |
| IPO Year | 2016 | 2021 |
| Metric | PTGX | ERO |
|---|---|---|
| Price | $99.57 | $27.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $108.23 | $36.50 |
| AVG Volume (30 Days) | 492.5K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $874.25 | $51.94 |
| Revenue Next Year | N/A | $2.43 |
| P/E Ratio | $2,044.80 | ★ $22.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.28 | $12.79 |
| 52 Week High | $107.84 | $39.80 |
| Indicator | PTGX | ERO |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 47.31 |
| Support Level | $96.20 | $23.47 |
| Resistance Level | $100.00 | $32.62 |
| Average True Range (ATR) | 4.42 | 1.55 |
| MACD | -0.22 | -0.13 |
| Stochastic Oscillator | 29.88 | 26.19 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.